Celularity Inc Ordinary Shares - Class A CELU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Celularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United States
-
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
-
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
-
Celularity Announces Naveen Jain to Join Board of Directors
-
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
-
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
-
Celularity Provides Update Regarding Nasdaq Listing Compliance
Trading Information
- Previous Close Price
- $0.94
- Day Range
- $0.86–0.96
- 52-Week Range
- $0.57–2.55
- Bid/Ask
- $0.93 / $0.93
- Shares Outstanding
- 32.45M
- Market Cap
- $30.18M
- Volume/Avg
- 252,414 / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.43
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 115
- Website
- https://www.celularity.com
Valuation
|
Metric
|
CELU
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.43 |
Price/Cash Flow | — |
Price/Earnings
CELU
Financial Strength
|
Metric
|
CELU
|
|---|---|
Quick Ratio | 0.09 |
Current Ratio | 0.11 |
Interest Coverage | −14.86 |
Quick Ratio
CELU
Profitability
|
Metric
|
CELU
|
|---|---|
Return on Assets (Normalized) | −33.47% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −180.68% |
Return on Assets
CELU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|kf^z>j | LOCK|lBD#? | $134B | |||
| Moderna Inc
MRNA
| LOCK|$$<<Qp! | LOCK|lC< | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?v<YQp | LOCK|tTQ&F | $84B | |||
| argenx SE ADR
ARGX
| LOCK|!LN?rB# | LOCK|>C< | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>%<$pz | LOCK|<%l | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@b%P^LT | LOCK|mpvM | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#$@lp&> | LOCK|F?Phd | $29B | |||
| Incyte Corp
INCY
| LOCK|z>KKPC> | LOCK|<^ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|%gzDjl# | LOCK|Tk | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|^B>%KN | LOCK|@jS | $14B |
United States